Switch theme
Sign up to access all valuation multiples
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
1998
350
LTM Revenue $1.1B
LTM EBITDA $708M
$7.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Halozyme Therapeutics has a last 12-month revenue (LTM) of $1.1B and a last 12-month EBITDA of $708M.
In the most recent fiscal year, Halozyme Therapeutics achieved revenue of $1.0B and an EBITDA of $657M.
Halozyme Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Halozyme Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | XXX | $1.0B | XXX | XXX | XXX |
| Gross Profit | $928M | XXX | $856M | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 84% | XXX | XXX | XXX |
| EBITDA | $708M | XXX | $657M | XXX | XXX | XXX |
| EBITDA Margin | 64% | XXX | 65% | XXX | XXX | XXX |
| EBIT | $630M | XXX | $551M | XXX | XXX | XXX |
| EBIT Margin | 57% | XXX | 54% | XXX | XXX | XXX |
| Net Profit | $520M | XXX | $444M | XXX | XXX | XXX |
| Net Margin | 47% | XXX | 44% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Halozyme Therapeutics's stock price is $56.
Halozyme Therapeutics has current market cap of $6.9B, and EV of $7.7B.
See Halozyme Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.7B | $6.9B | XXX | XXX | XXX | XXX | $4.69 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Halozyme Therapeutics has market cap of $6.9B and EV of $7.7B.
Halozyme Therapeutics's trades at 7.5x EV/Revenue multiple, and 11.7x EV/EBITDA.
Equity research analysts estimate Halozyme Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Halozyme Therapeutics has a P/E ratio of 13.3x.
See valuation multiples for Halozyme Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.9B | XXX | $6.9B | XXX | XXX | XXX |
| EV (current) | $7.7B | XXX | $7.7B | XXX | XXX | XXX |
| EV/Revenue | 6.9x | XXX | 7.5x | XXX | XXX | XXX |
| EV/EBITDA | 10.8x | XXX | 11.7x | XXX | XXX | XXX |
| EV/EBIT | 12.2x | XXX | 13.9x | XXX | XXX | XXX |
| EV/Gross Profit | 8.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.3x | XXX | 15.5x | XXX | XXX | XXX |
| EV/FCF | 14.6x | XXX | 16.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHalozyme Therapeutics's last 12 month revenue growth is 21%
Halozyme Therapeutics's revenue per employee in the last FY averaged $2.9M, while opex per employee averaged $0.9M for the same period.
Halozyme Therapeutics's rule of 40 is 75% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Halozyme Therapeutics's rule of X is 116% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Halozyme Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | 64% | XXX | 65% | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | 34% | XXX | XXX | XXX |
| Rule of 40 | 75% | XXX | 86% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 116% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 30% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Halozyme Therapeutics acquired XXX companies to date.
Last acquisition by Halozyme Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Halozyme Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Halozyme Therapeutics founded? | Halozyme Therapeutics was founded in 1998. |
| Where is Halozyme Therapeutics headquartered? | Halozyme Therapeutics is headquartered in United States of America. |
| How many employees does Halozyme Therapeutics have? | As of today, Halozyme Therapeutics has 350 employees. |
| Who is the CEO of Halozyme Therapeutics? | Halozyme Therapeutics's CEO is Dr. Helen I. Torley, M.R.C.P.,MB.Ch.B.. |
| Is Halozyme Therapeutics publicy listed? | Yes, Halozyme Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Halozyme Therapeutics? | Halozyme Therapeutics trades under HALO ticker. |
| When did Halozyme Therapeutics go public? | Halozyme Therapeutics went public in 2004. |
| Who are competitors of Halozyme Therapeutics? | Similar companies to Halozyme Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Halozyme Therapeutics? | Halozyme Therapeutics's current market cap is $6.9B |
| What is the current revenue of Halozyme Therapeutics? | Halozyme Therapeutics's last 12 months revenue is $1.1B. |
| What is the current revenue growth of Halozyme Therapeutics? | Halozyme Therapeutics revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Halozyme Therapeutics? | Current revenue multiple of Halozyme Therapeutics is 6.9x. |
| Is Halozyme Therapeutics profitable? | Yes, Halozyme Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Halozyme Therapeutics? | Halozyme Therapeutics's last 12 months EBITDA is $708M. |
| What is Halozyme Therapeutics's EBITDA margin? | Halozyme Therapeutics's last 12 months EBITDA margin is 64%. |
| What is the current EV/EBITDA multiple of Halozyme Therapeutics? | Current EBITDA multiple of Halozyme Therapeutics is 10.8x. |
| What is the current FCF of Halozyme Therapeutics? | Halozyme Therapeutics's last 12 months FCF is $526M. |
| What is Halozyme Therapeutics's FCF margin? | Halozyme Therapeutics's last 12 months FCF margin is 47%. |
| What is the current EV/FCF multiple of Halozyme Therapeutics? | Current FCF multiple of Halozyme Therapeutics is 14.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
